Spectral Diagnostics, Inc. Joins OTCQX
NEW YORK, Jan. 11, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the financial information and technology services company that provides the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, announced that Spectral Diagnostics, Inc. (OTCQX: DIAGF
; TSX: SDI), a Phase III company seeking U.S. FDA approval of its product for treating severe sepsis and septic shock, is now trading on the highest tier of the OTC market, OTCQX®.
Spectral Diagnostics began trading today on the OTC market's prestigious tier, OTCQX International. Investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
"The OTCQX platform offers investor-focused companies a winning combination of quality control, transparency, and broader visibility to U.S. investors," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Spectral Diagnostics to OTCQX."
Brean Murray, Carret & Co. will serve as Spectral Diagnostic's Principal American Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements. http://ih.advfn.com/p.php?pid=nmona&article=50702028&symbol=DIAGF